Explore
Validate
Learn
Western blot
ImmunoprecipitationAntibody data
- Antibody Data
- Antigen structure
- References [13]
- Comments [0]
- Validations
- Western blot [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN151785 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-BRCA1 Associated RING Domain 1 (BARD1) (AA 250-300) antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 250-300
- Vial size
- 100 μL
- Storage
- Store at 4°C. Do not freeze.
- Handling
- Do not freeze.
Submitted references The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function.
The in vivo dynamic organization of BRCA1-A complex proteins at DNA damage-induced nuclear foci.
Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome.
BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair.
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.
HERC2 is an E3 ligase that targets BRCA1 for degradation.
Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.
Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2.
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
BARD1 translocation to mitochondria correlates with Bax oligomerization, loss of mitochondrial membrane potential, and apoptosis.
Oncogenic BARD1 isoforms expressed in gynecological cancers.
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Tembe V, Martino-Echarri E, Marzec KA, Mok MT, Brodie KM, Mills K, Lei Y, DeFazio A, Rizos H, Kettle E, Boadle R, Henderson BR
Cellular signalling 2015 Sep;27(9):1763-71
Cellular signalling 2015 Sep;27(9):1763-71
The in vivo dynamic organization of BRCA1-A complex proteins at DNA damage-induced nuclear foci.
Mok MT, Henderson BR
Traffic (Copenhagen, Denmark) 2012 Jun;13(6):800-14
Traffic (Copenhagen, Denmark) 2012 Jun;13(6):800-14
Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome.
Zhang YQ, Pilyugin M, Kuester D, Leoni VP, Li L, Casula G, Zorcolo L, Schneider-Stock R, Atzori L, Irminger-Finger I
British journal of cancer 2012 Aug 7;107(4):675-83
British journal of cancer 2012 Aug 7;107(4):675-83
BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair.
Chapman JR, Sossick AJ, Boulton SJ, Jackson SP
Journal of cell science 2012 Aug 1;125(Pt 15):3529-34
Journal of cell science 2012 Aug 1;125(Pt 15):3529-34
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.
Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, Norris G, Nguyen le B, Jagannathan J, Laquaglia M, Winter C, Diamond M, Hou C, Attiyeh EF, Mosse YP, Pineros V, Dizin E, Zhang Y, Asgharzadeh S, Seeger RC, Capasso M, Pawel BR, Devoto M, Hakonarson H, Rappaport EF, Irminger-Finger I, Maris JM
Cancer research 2012 Apr 15;72(8):2068-78
Cancer research 2012 Apr 15;72(8):2068-78
HERC2 is an E3 ligase that targets BRCA1 for degradation.
Wu W, Sato K, Koike A, Nishikawa H, Koizumi H, Venkitaraman AR, Ohta T
Cancer research 2010 Aug 1;70(15):6384-92
Cancer research 2010 Aug 1;70(15):6384-92
Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
De Nicolo A, Parisini E, Zhong Q, Dalla Palma M, Stoeckert KA, Domchek SM, Nathanson KL, Caligo MA, Vidal M, Cusick ME, Garber JE
Cancer research 2009 Sep 1;69(17):7030-7
Cancer research 2009 Sep 1;69(17):7030-7
BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.
Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M, Ohta T
Cancer research 2009 Jan 1;69(1):111-9
Cancer research 2009 Jan 1;69(1):111-9
Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2.
Ryser S, Dizin E, Jefford CE, Delaval B, Gagos S, Christodoulidou A, Krause KH, Birnbaum D, Irminger-Finger I
Cancer research 2009 Feb 1;69(3):1125-34
Cancer research 2009 Feb 1;69(3):1125-34
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
De Nicolo A, Tancredi M, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G, Drapkin R, Caligo MA
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jul 15;14(14):4672-80
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jul 15;14(14):4672-80
BARD1 translocation to mitochondria correlates with Bax oligomerization, loss of mitochondrial membrane potential, and apoptosis.
Tembe V, Henderson BR
The Journal of biological chemistry 2007 Jul 13;282(28):20513-22
The Journal of biological chemistry 2007 Jul 13;282(28):20513-22
Oncogenic BARD1 isoforms expressed in gynecological cancers.
Li L, Ryser S, Dizin E, Pils D, Krainer M, Jefford CE, Bertoni F, Zeillinger R, Irminger-Finger I
Cancer research 2007 Dec 15;67(24):11876-85
Cancer research 2007 Dec 15;67(24):11876-85
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, Li R
Oncogene 2005 Dec 15;24(56):8343-8
Oncogene 2005 Dec 15;24(56):8343-8
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
